B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Eton Pharmaceuticals (ETON) today and set a price target of $14.50. The company’s shares closed last Monday at $6.01.
According to TipRanks.com, D’silva has 0 stars on 0-5 star ranking scale with an average return of -6.0% and a 31.4% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, EyePoint Pharmaceuticals, and Sensus Healthcare.
Eton Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $17.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.20 and a one-year low of $5.13. Currently, Eton Pharmaceuticals has an average volume of 121.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
